Risk status at selexipag initiation in pulmonary arterial hypertension (PAH): Insights from EXPOSURE

S. Gaine (Dublin, Ireland), P. Escribano (Madrid, Spain), P. Biedermann (Allschwil, Switzerland), A. Muller (Allschwil, Switzerland), H. Sun (Allschwil, Switzerland), S. Söderberg (Umeå, Sweden), T. Lange (Regensburg, Germany)

Source: Virtual Congress 2020 – Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension
Session: Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension
Session type: E-poster session
Number: 1523
Disease area: Pulmonary vascular diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Gaine (Dublin, Ireland), P. Escribano (Madrid, Spain), P. Biedermann (Allschwil, Switzerland), A. Muller (Allschwil, Switzerland), H. Sun (Allschwil, Switzerland), S. Söderberg (Umeå, Sweden), T. Lange (Regensburg, Germany). Risk status at selexipag initiation in pulmonary arterial hypertension (PAH): Insights from EXPOSURE. 1523

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: